INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.23, pp.16-19, 2014 (SCI-Expanded)
Background: Tigecycline is a relatively new glycylcycline antimicrobial, active in vitro against a variety of Gram-positive and Gram-negative organisms. In this study we evaluated the outcomes of spondylodiscitis cases treated with tigecycline-including therapies retrospectively.